UNSPSC 51372032: Morphine hydrochloride trihydrate

This classification denotes an opiate C17H19NO3.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q5F3AS69LF, chemically known as morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-, hydrochloride, trihydrate, but more generally known as morphine hydrochloride trihydrate, which bears US NIH Compound Identifier 5492889. European Medicines Agency schedules Morphine hydrochloride trihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27294.

Most nations, for tariff and trade purposes, schedule morphine hydrochloride trihydrate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE HYDROCHLORIDE TRIHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.O.O.CL.

UNSPSC 51372032 Morphine hydrochloride trihydrate is a Commodity code representing a single pharmaceutical product line. State and local procurement activity under this code focuses on acquisition of pharmaceutical products—including opioids and related medications—for public health, emergency response, and community health initiatives. Recent solicitations show state and local governments buying naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services commissions, and multi-state purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers shared contracts across member jurisdictions, while individual counties and state agencies conduct direct procurements for specific operational needs.

Geographic activity spans at least Florida, Texas, Minnesota, and Oregon, with the most visible recent solicitations centered on state-level cooperative purchasing mechanisms and regional health authority acquisitions. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023, in response to community health and emergency preparedness demand. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to reshape pharmaceutical procurement outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to meet cGMP and Drug Supply Chain Security Act compliance and maintain relationships with authorized wholesalers including AmerisourceBergen (Cencora) and Cardinal Health.